Clinical Trial Update: Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating siltuximab to prevent cytokine release syndrome in patients with relapsed/refractory multiple myeloma treated with teclistamab has be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And Refractory Multiple Myeloma
• Cytokine Release Syndrome
• Immune Effector Cell Associated Neurotoxicity Syndrome
• Multiple Myeloma

Drugs mentioned

• Sylvant (siltuximab)
• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Jack Khouri, MD | Conditions: Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Status: WITHDRAWN